Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

The Health Care sector as a whole closed the day down 0.5% versus the S&P 500, which was unchanged. Laggards within the Health Care sector included Escalon Medical ( ESMC), down 5.8%, Reliv' International ( RELV), down 2.4%, Tianyin Pharmaceutical ( TPI), down 3.6%, Dynatronics ( DYNT), down 6.2% and VBI Vaccines ( VBIV), down 4.8%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today:

Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies that pushed the Health Care sector lower today. Fresenius Medical Care AG & Co. KGaA was down $2.12 (4.9%) to $41.04 on heavy volume. Throughout the day, 420,276 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 145,200 shares. The stock ranged in price between $39.74-$41.17 after having opened the day at $40.41 as compared to the previous trading day's close of $43.16.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co. KGaA has a market cap of $26.4 billion and is part of the health services industry. Shares are up 16.2% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Fresenius Medical Care AG & Co. KGaA a buy, 1 analyst rates it a sell, and 5 rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from TheStreet Ratings analysis on FMS go as follows:

  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 30.05% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, FMS should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 12.3%. Since the same quarter one year prior, revenues rose by 11.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The debt-to-equity ratio is somewhat low, currently at 0.95, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.07, which illustrates the ability to avoid short-term cash problems.
  • Net operating cash flow has significantly increased by 298.30% to $447.27 million when compared to the same quarter last year. In addition, FRESENIUS MEDICAL CARE AG&CO has also vastly surpassed the industry average cash flow growth rate of -14.36%.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500, but is less than that of the Health Care Providers & Services industry average. The net income increased by 2.0% when compared to the same quarter one year prior, going from $205.46 million to $209.55 million.

You can view the full analysis from the report here: Fresenius Medical Care AG & Co. KGaA Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, VBI Vaccines ( VBIV) was down $0.13 (4.8%) to $2.60 on light volume. Throughout the day, 1,022 shares of VBI Vaccines exchanged hands as compared to its average daily volume of 6,800 shares. The stock ranged in price between $2.55-$2.60 after having opened the day at $2.56 as compared to the previous trading day's close of $2.73.

VBI Vaccines has a market cap of $53.2 million and is part of the health services industry. Shares are down 18.0% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates VBI Vaccines a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Reliv' International ( RELV) was another company that pushed the Health Care sector lower today. Reliv' International was down $0.03 (2.4%) to $1.22 on light volume. Throughout the day, 3,335 shares of Reliv' International exchanged hands as compared to its average daily volume of 8,500 shares. The stock ranged in price between $1.20-$1.28 after having opened the day at $1.21 as compared to the previous trading day's close of $1.25.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, wellness needs, weight management, and sports nutrition. Reliv' International has a market cap of $15.8 million and is part of the health services industry. Shares are up 5.1% year-to-date as of the close of trading on Wednesday.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • RELV's revenue growth has slightly outpaced the industry average of 2.6%. Since the same quarter one year prior, revenues slightly increased by 2.5%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • RELV's debt-to-equity ratio is very low at 0.24 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.90 is somewhat weak and could be cause for future problems.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Personal Products industry and the overall market, RELIV INTERNATIONAL INC's return on equity is below that of both the industry average and the S&P 500.
  • RELV has underperformed the S&P 500 Index, declining 16.45% from its price level of one year ago. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.

You can view the full analysis from the report here: Reliv' International Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.